Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_4
3
75%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 43 (75.0%)

Trials by Status

terminated250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_4

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery

NCT05317364
terminatedphase_4

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

NCT02213757
completedphase_3

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

NCT02195986
completedphase_4

Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse

NCT03779633

Clinical Trials (4)

Showing 4 of 4 trials
NCT05317364Phase 4

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery

Terminated
NCT02213757Phase 4

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

Terminated
NCT02195986Phase 3

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

Completed
NCT03779633Phase 4

Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4